Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Trifluridine/tipiracil in patients with refractory metastatic colorectal cancer in clinical routine in Germany: Interim results of the non-interventional study TACTIC – Interim results of the non-interventional study TACTIC

Schwaner I, Göhler T, Decker T, Grundeis M, Sauer A, Fichter C, Moorahrend E, Kröning H, Lipke J, Kojouharoff G, Frank M, Hogrefe C, Marschner N, Potthoff K, 2020

Oncol Res Treat. 2020;43(suppl 4)(301):130.

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: -
TACTIC
2020
Changes in routine care treatment of patients with multiple myeloma in Germany – results from the MYRIAM registry

Engelhardt M, Knauf W, Lipke J, Reiser M, Dörfel S, Kortüm M, Schlag R, von der Heyde E, La Rosée P, Pfannes R, Houet L, Medinger T, Jänicke M, Marschner N, 2020.

Oncol Res Treat. 2020;43(suppl 4)(70):108.

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
MYRIAM
2020
1st-line Panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany – Interim results of the non-interventional study VALIDATE

J. Uhlig, J. Potenberg, D. Semsek, P. Stübs, C. Fichter, A. Köhler, L. Müller, M. Reiser, H.U. Siebenbach, T. Göhler, L. Jacobasch, V. Kächele, B. Timm, K. Potthoff, N. Marschner, 2020

Download

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ESMO / Journal: -
VALIDATE
2020
Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C – real-world data from the German observational, prospective, nation-wide CRISP Registry (AIO-TRK-0315)

Griesinger F, Eberhardt WEE2, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K, Alt J, Schütte W, Jänicke M, Fleitz A, Zacharias S, Hipper A, Buller M, Weichert W, Groschek M, von der Heyde E, Rauh J, Dechow T, Sebastian M, Thomas M, 2020

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: -
CRISP
2020
What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL

A. Welt, M. Thill, E. Stickeler, M.-O. Zahn, A. Nusch, M. Zaiss, U. Neef, S. Fruehauf, R. Buss-Steidle, V. Hagen, M. Chiabudini, L. Kruggel, M. Jänicke, N. Marschner, A. Wöckel, N. Harbeck, T. Decker, 2020

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: -
OPAL
2020
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

Staehler, M, Panic, A, Goebell, PJ, Merling, M, Potthoff, K, Herrmann, E, de Geeter, P, Vannier, C, Hogrefe, C, Marschner, N, Grünwald, V, 2020.

Int J Cancer. 2020;1-11.

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: / Journal: International Journal of Cancer
FLIPPER
2020
Patient, nurse and physician preferences: Final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or On-body injector (OBI) in cancer patients

M. Metz, D. Semsek, G. Rogmans, U. Hutzschenreuter, T. Fietz, J. Harde, S. Zacharias, C. Hielscher, A. Lorenz, M.-O. Zahn, D. Guth, S. Grebhardt, C. Fichter, K. Potthoff, 2020.

Download

Indikation: Mammakarzinom / Veranstaltung: ESMO / Journal: -
CONVENIENCE
2020
REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL).

Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020.

HemaSphere 4(S1) (EP1245), 583.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: HemaSphere
REFLECT
2020
REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL).

Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020.

J Clin Oncol 38 no. 15_suppl (May 20, 2020) 8060-8060. DOI: 10.1200/JCO.2020.38.15_suppl.8060

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
REFLECT
2020
Real-world effectiveness of nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC: Results of the second interim analysis of the NEPTUN study.

Dechow T, Riera-Knorrenschild J, Hackanson B, Fischer von Weikersthal L, Schulz H, Chiabudini M, Timm B, Zerbes R, Potthoff K, 2020.

J Clin Oncol 38: 2020 (suppl; abstr e21611) doi: 10.1200/JCO.2020.38.15_suppl.e21611

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
NEPTUN
2020